Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-13 Etrasimod

Techniker Krankenkasse · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

October 31, 2028
Response Due
Active
Status

Opportunity Overview

Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130c Abs. 1 SGB V zu dem Wirkstoff Etrasimod im Rahmen eines Open-House-Verfahrens.

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyTechniker Krankenkasse
CountryGermany
CategoryPharmaceuticals
PublishedSeptember 17, 2026
Procurement stageRequest for Proposal (RFP)
Response dueOctober 31, 2028
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Ticagrelor, ATC B01AC24
Germany – Pharmaceutical products – Arzneimittelverträge mit Beitrittsoption
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Lopinavir und Ritonavir (ATC-Code: J05AR10).
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Formoterol (ausschl. IHP in der Wirkstärke 6 µg), ATC R03AC13 f. d. Z. 1.10.26-30.9.28 (zzgl. V.-Opt.1x12 M.)
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Follitropin alfa (ATC: G03GA05)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Colecalciferol, ohne Rx-Sortiment, ATC A11CC05
Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-15
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Erythropoietin (ATC: B03XA01 - in der Wirkstärke über 10.000 IE je Dosiereinheit)

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.